Who Benefits From 5 Years of Extended Endocrine Therapy? Who Benefits From 5 Years of Extended Endocrine Therapy?
MammaPrint genomic testing suggests that only patients with low-risk, not ultra-low-risk or high-risk, breast cancer benefit from 5 years of extended endocrine therapy.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 22, 2022 Category: Pathology Tags: Hematology-Oncology News Source Type: news
First - Line Regimens With Endocrine Therapy Show Benefits in Breast Cancer
Findings seen among subgroup of patients with human epidermal growth factor receptor 2 - positive metastatic breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 20, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news
First-Line Regimens With Endocrine Therapy Show Benefits in Breast Cancer
TUESDAY, Dec. 20, 2022 -- First-line regimens with endocrine therapy (ET) may be associated with benefits among patients with human epidermal growth factor receptor 2-positive (ERBB2-positive [formerly HER2-positive]) metastatic breast cancer (MBC),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2022 Category: Pharmaceuticals Source Type: news
SABCS: Interrupting Endocrine Therapy Does Not Pose Breast Cancer Recurrence Risk
Findings seen among young women with early - stage, hormone receptor - positive breast cancer desiring pregnancy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 14, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
SABCS: Interrupting Endocrine Therapy Does Not Pose Breast Cancer Recurrence Risk
WEDNESDAY, Dec. 14, 2022 -- For young women with early-stage hormone receptor (HR)-positive breast cancer (BC) desiring pregnancy, temporary interruption of endocrine therapy does not confer a greater short-term risk for recurrence than not... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 14, 2022 Category: Pharmaceuticals Source Type: news
CTC-guided Therapy Beats Physician Choice in Met Breast Cancer CTC-guided Therapy Beats Physician Choice in Met Breast Cancer
Better survival was seen when treatment choice between chemotherapy and endocrine therapy in women with HR+/HER2- metastatic breast cancer was guided by circulating tumor cell (CTC) counts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
SABCS: Updated Analysis Confirms Endocrine Therapy Effective With/Without Chemo
Findings seen among HR - positive, HER2 - negative, node - negative early breast cancer patients with recurrence score of 11 to 25 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 12, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
Women Can Safely Interrupt Endocrine Tx to Pursue Pregnancy Women Can Safely Interrupt Endocrine Tx to Pursue Pregnancy
Interrupting endocrine therapy may allow three quarters of women with hormone receptor positive breast cancer to achieve pregnancy, while having no impact on their short-term outcomes, new data suggest.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
SABCS: Updated Analysis Confirms Endocrine Therapy Effective With/Without Chemo
MONDAY, Dec. 12, 2022 -- For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative early breast cancer (EBC) with a 21-gene recurrence score (RS) of 11 to 25, adjuvant endocrine therapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2022 Category: Pharmaceuticals Source Type: news
Adjuvant Ibandronate in Postmenopausal ER+ Breast Cancer Adjuvant Ibandronate in Postmenopausal ER+ Breast Cancer
Data from the TEAM-IIB trial provides insight into the effects of ibandronate treatment combined with endocrine therapy among this subgroup of breast cancer patients.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 16, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Oral, Hormone-Free Med Reduces Hot Flashes in Breast Cancer Patients
(MedPage Today) -- A novel, non-hormonal oral drug was effective in reducing hot flashes and night sweats in women taking oral adjuvant endocrine therapy after breast cancer, according to results from a phase II study.
After 28 days of treatment... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 12, 2022 Category: Hematology Source Type: news
Vaginal Estrogen Not Recommended With Aromatase Inhibitors Vaginal Estrogen Not Recommended With Aromatase Inhibitors
New data show, for the first time, that the use of vaginal estrogen therapy to alleviate side effects of adjuvant endocrine therapy may increase the risk for breast cancer recurrence.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 21, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
No Benefit From Endocrine Therapy After Mastectomy for DCIS No Benefit From Endocrine Therapy After Mastectomy for DCIS
Chinese investigators recommend ending the practice in patients with hormone-positive ductal carcinoma in situ. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Response to Neoadjuvant Endocrine Therapy for Breast Cancer May Vary by Race
TUESDAY, Sept. 20, 2022 -- The response to neoadjuvant endocrine therapy (NET) for hormone receptor-positive breast cancer (HR+BC) may vary by race, according to a study presented at the 15th AACR Conference on the Science of Cancer Health... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2022 Category: Pharmaceuticals Source Type: news
Best Use of Adjuvant Endocrine Therapy in HR-low Breast Cancer? Best Use of Adjuvant Endocrine Therapy in HR-low Breast Cancer?
The findings shed light on a contentious debate. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
